Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results
Date:2/24/2011

for acute treatment of HAE. There can be no assurance that the FDA or EMEA will not require additional or unanticipated studies or clinical trial outcomes before granting regulatory approval of any of our product candidates, or that we will be successful in gaining regulatory approval of any of our product candidates. Biologics such as Cinryze require processing steps that are more difficult than those required for most chemical pharmaceuticals, and as such we cannot assure you that the industrial scale process will be considered by the FDA to be equivalent to our existing manufacturing process. The FDA may view the data regarding equivalence of the industrial scale manufacturing process as insufficient or inconclusive, request additional data, require additional conformance batches, delay any decision past the time frames anticipated by us, or deny the approval of the industrial scale manufacturing process. If the manufacturing capacity expansion projects at Sanquin are delayed, or do not result in the capacity we anticipate, if Sanquin cannot obtain necessary regulatory approvals for the contemplated facility expansions in the time frames we anticipate or if we are not able to manufacture the anticipated volume of product at the existing scale, we may not be able to satisfy patient demand. Our inability to obtain adequate product supplies to satisfy our patient demand may create opportunities for our competitors and we will suffer a loss of potential future revenues. These factors, and other factors, including, but not limited to those described in ViroPharma's annual report on Form 10-K for the year ended December 31, 2010, could cause future results to differ materially from the expectations expressed in this press release. The forward-looking statements contained in this press release may become outdated over time. ViroPharma does not assume any responsibility for updating any forward-looking statements. VIROPHARMA INCORPORATEDSelected Financial InformationCon
'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. ViroPharma to Present at Three September Healthcare Conferences
2. ViroPharma to Present at Three October Healthcare Conferences
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
5. ViroPharma to Present at Three November Healthcare Conferences
6. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
7. ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes
8. ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009
9. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
10. ViroPharma Incorporated Honored by the National Organization for Rare Disorders
11. ViroPharma to Present at Two June Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Md. , Aug. 19, 2014   ... biotechnology company developing novel anti-infective biologic and drug ... and diseases, announced today that its novel ... at the 54 th Interscience Conference on ... Washington D.C. ...
(Date:8/18/2014)... A new therapy developed by researchers at the ... Medicine and Columbia University Medical Center (CUMC) may ... disease treatment. , The researchers demonstrated in ... could selectively inhibit blood vessel re-narrowing and simultaneously ... a balloon catheter to open narrowed or blocked ...
(Date:8/18/2014)... and data storage may someday run on ... to read and write digital information, outperforming ... But ferroelectrics must first overcome a few ... of "forgetting" stored data. , Now, ... Brookhaven National Laboratory have discovered nanoscale asymmetries ...
(Date:8/18/2014)... 18, 2014 TNI BioTech, Inc. (OTC-BB: TNIB) ... manufacturing and marketing of innovative therapies for autoimmune diseases ... providing a second notice of TNI BioTech,s annual meeting ... announcement, Noreen Griffin , founder and CEO of ... your participation in the Annual Meeting. On behalf of ...
Breaking Biology Technology:Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 2Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 4Selective therapy may improve artery repair after interventional cardiovascular procedures 2Selective therapy may improve artery repair after interventional cardiovascular procedures 3Promising ferroelectric materials suffer from unexpected electric polarizations 2Promising ferroelectric materials suffer from unexpected electric polarizations 3Promising ferroelectric materials suffer from unexpected electric polarizations 4TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 2TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 3TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 4
... (Nasdaq:,AWRE), a leading supplier of broadband technology and biometrics ... an extension to,the program originally authorized on August 28, ... up to $5 million worth of shares of,the Company,s ... until December,31, 2009 at prevailing market prices. The Board ...
... Net Revenues, $0.10 Net Income Per Share, SAN ... VNUS ), a leading provider of medical devices,for ... its,financial results for the third quarter ended September 30, ... 2008 increased 32% to $23.1,million compared with $17.5 million ...
... Transgenomic, Inc. (OTC,Bulletin Board: TBIO) today announced financial results ... results are presented in,the tables that follow., Third ... $5.4 million during the third,quarter of 2008, compared to ... from continuing operations was $2.9 million or 54,percent during ...
Cached Biology Technology:Aware, Inc. Announces Extension of Stock Repurchase Plan 2VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007 2VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007 3VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007 4VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007 5VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007 6VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007 7VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007 8VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007 9VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007 10Transgenomic, Inc. Reports Third Quarter 2008 Results 2Transgenomic, Inc. Reports Third Quarter 2008 Results 3Transgenomic, Inc. Reports Third Quarter 2008 Results 4Transgenomic, Inc. Reports Third Quarter 2008 Results 5Transgenomic, Inc. Reports Third Quarter 2008 Results 6Transgenomic, Inc. Reports Third Quarter 2008 Results 7
(Date:8/19/2014)... Daylight was breaking over the central Pacific and ... about a dozen scientists strategized for the day ahead. ... to collect water samples around the southern Line Islands, ... gizmos and delicate machinery strewn throughout the 158-foot research ... research group to bring a DNA sequencer out into ...
(Date:8/18/2014)... , August 19, 2014 ... biometric authentication in smart devices  Trustonic, ... for smart devices, and Fingerprint Cards AB (FPC) ... of FIDO Ready™ secure biometric authentication on connected ... touch fingerprint sensors (FPC1020, FPC1021 and FPC1150) and ...
(Date:8/18/2014)... species native to a major Arizona watershed may lose ... as surface water flow is reduced by the effects ... these fish species, found in the Verde River Basin, ... easy access to various resources throughout the river and ... (Rhinichthys osculus), roundtail chub (Gila robusta) and Sonora sucker ...
Breaking Biology News(10 mins):Sequencing at sea 2Sequencing at sea 3Trustonic and Fingerprint Cards Collaborate to Bring Secure Biometrics to Connected Devices 2Trustonic and Fingerprint Cards Collaborate to Bring Secure Biometrics to Connected Devices 3Trustonic and Fingerprint Cards Collaborate to Bring Secure Biometrics to Connected Devices 4Climate change will threaten fish by drying out Southwest US streams, study predicts 2Climate change will threaten fish by drying out Southwest US streams, study predicts 3
... , RIDGE, N.Y., Oct. 21 What,s the cost ... preventing accidental death resulting from prescription medication abuse, there,s ... be unaware that the lock-boxes they,ve installed are not ... drugs. That,s why MEDNET(TM), a national leader in premium-quality ...
... CHAPEL HILL Scientists at the University of ... the University of California, San Francisco have developed and ... for existing drugs. The researchers developed a computational ... known drugs are to the naturally occurring binding partners ...
... 4, 2009) For more than 25 years, all ... Strombus gigas ) have been unsuccessfuluntil now. For the ... beaded (nucleated) and non-beaded cultured pearls from the queen ... University,s Harbor Branch Oceanographic Institute (HBOI). With less than ...
Cached Biology News:MEDNET Launches MedSafe to Prevent Teenage Prescription Drug Abuse 2MEDNET Launches MedSafe to Prevent Teenage Prescription Drug Abuse 3Study points to new uses, unexpected side effects of already existing drugs 2Scientists are first to 'unlock' the mystery of creating cultured pearls from the queen conch 2Scientists are first to 'unlock' the mystery of creating cultured pearls from the queen conch 3
... Ac-DEVD-CHO is an inhibitor ... The concentration of inhibitor ... activity must be determined ... Ten micromolar inhibitor is ...
Human RELT/TNFRSF19L MAb (Clone 238104)...
homeo box D3, mRNA...
Human TSLP MAb (Clone 258136)...
Biology Products: